ANTONIO P.PALUMBO
Curriculum vitae
Dati personali
Data di nascita
Luogo di nascita
Cittadinanza
14 Aprile, 1956
Torino, Italy
Italiana
Studi effettuati
1974
1980
1985
1989
Maturità scientifica, Liceo Galileo Ferrarsi, Torino,
Laurea in Medicina e Chirurgia, Università di Torino,
Specializzazione in Oncologia, Università di Torino,
Specializzazione in Ematologia, Università di Modena,
Dati professionali
2006-oggi
2006-oggi
1989-2006
1994
1987-1989
1985-1986
1982-1984
Professore Associato, Malattie del Sangue, Università di Torino
SSCVD Mieloma Multiplo Clinical Trial in Oncoematologia,
Dipartimento di Oncologia, Azienda Ospedaliera Universitaria S.
Giovanni Battista di Torino
Dirigente Medico I livello, Divisione Universitaria di Ematologia,
Azienda Ospedaliera S. Giovanni Battista di Torino
Visiting Physician, MD Anderson, University of Texas, Houston, USA
Borsista presso l’Università di Torino
Research Associate, Wistar Institute, University of Pennsylvania,
Philadelphia, USA
Visiting Scientist, Wistar Insitute, University of Pennsylvania,
Philadelphia, USA
Società professionali
-
Membro della Società Italiana di Ematologia (SIE)
Membro della Società Italiana di Ematologia Sperimentale (SIES)
Membro della Società Europea di Ematologia (EHA)
Membro della Società Americana di Ematologia (ASH)
Membro della Società Americana di Oncologia Clinica (ASCO)
Presidente European Myeloma Network Trialist Group (EMNTG)
Board od Directors International Myeloma society (IMS)
Interessi clinico- scientifici
Mielomagenesi, microambiente e traslocazioni mieloma correlate
Mieloma Multiplo: approcci terapeutici intensificati nel paziente anziano
Mieloma Multiplo: terapie ad alte dosi con supporto di cellule staminali
Mieloma multiplo: nuove strategie terapeutiche (Talidomide, Bortezomid, Lenalinomide)
Pubblicazioni
1
Oltre 500 abstract presentati a Convegni Scientfici e 169 contributi scientifici peer-reviewed
(Impact Factor totale 924.857)
ELENCO PUBBLICAZIONI
Impact Factor 924.857 (ref. 1-169)
1. Palumbo A, Turco GL, Brossa C, D'Alberto M, Giovinazzo B, e Pegoraro L: Recettori insulinici nelle
cellule della linea promielocitaria umana HL60. Boll Soc It Biol Sper.1980; 56:1345-1349.
2. Palumbo A, Turco GL, Brossa C, D,Alberto M, Ghezzo F, e Pegoraro L: Modificazioni
dell'attivita'legante l'insulina di cellule leucemiche umane durante la differenziazione indotta da sostanze
chimiche. Boll Soc It Biol Sper. 1980; 56:1350-1354.
3. Ghezzo F, Palumbo A, e Pegoraro L: Modificazioni dell'attivita' fibrinolitica di cellule di leucemia
umana della linea HL60 in risposta ad agenti promuoventi la differenziazione. Boll Soc It Biol Sper.
1980;56:1355-1359.
4. Palumbo A, Turco GL, Ghezzo F, e Pegoraro L: Decrease in insulin binding activity during HL60
human promyelocytic cell line myeloid differentiation. Hemolymphopoiesis: normal and pathological cell
differentiation. Esculapio ed. 1980. 317-320.
5. Ghezzo F, Giovinazzo B, Palumbo A, e Pegoraro L: Changes of lysosomal enzyme activities during
retinoic acid induced myeloid differentiation of human promyelocytic HL60 cell line. Hemolymphopoiesis:
normal and pathological cell differentiation. Esculapio ed. 1980. 321- 324.
6. Ghezzo F, Palumbo A, e Pegoraro L: Fibrinolytic activity in normal and leukemic myeloid
differentiation. Haematologica. 1982; 67:17-22. (I.F. 5.032)
7. Ioverno L, Levis A, Palumbo A, Ghezzo F, Genetta C, e Pegoraro L: Attivita' fagocitaria e
caratteristiche citochimiche in cellule di leucemie acute umane mieloblastiche. Boll Soc It Biol Sper. 1982;
58:267-270.
8. Palumbo A, Giovinazzo B, Marmont F, Garbarino G, Paolino F, e Pegoraro L: Espressione della
struttura HLA-DR e di un antigene di membrana specifico per la linea granulocitopoietica sui blasti di
leucemia acuta. Boll Soc It Biol Sper. 1982; 58:271-274.
9. Palumbo A, Brossa C, Turco GL, e Pegoraro L: Changes in insulin binding activity during myeloid
differentiation. Endocrinology. 1983; 112:965-970. (I.F. 5.236)
10. Pegoraro L, Matera L, Ritz J, Levis A, Palumbo A, e Biagini G: Establishment of A Ph1-positive
human cell line (BV173). J Natl Can Inst. 1983; 70:447-453. (I.F. 13.847)
11. Matera l, Foa R, Marmont F, Massaia M, Palumbo A, e Pegoraro L: Changes in SRBC binding
capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0tetradecanoilphorbol-13-acetate (TPA). J Clin Lab Immunol. 1983; 12:57-61. (I.F. 2.748)
12. Pessano S, Bottero L, Faust J, Trucco M, Palumbo A, Pegoraro L, Lange B, Brezin C, Borst J, Terhorst
C, e Rovera G: Differentiation antigens of human hemopoietic cells: patterns of reactivity of two
monoclonal antibodies. Cancer Research. 1983; 43:4812-4815. (I.F. 7.656)
13. Selden JR, Emanuel BS, Wang E, Cannizzaro L, Palumbo A, Erikson J, Nowell PC, Rovera G, e Croce
CM: Amplified c-lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
Proc Natl Acad Sci USA. 1983; 80:7289-7292. (I.F. 9.643)
14. Pessano S, Ferrero D, Palumbo A, Bottero L, Hubbel H, Lange B, e Rovera G: Differentiation antigens
2
of normal and leukemic myelomonocytic cells. UCLA Symposia on Molecular and Cellular Biology. New
Series, vol. 9, Normal and Neoplastic Hematopoiesis (Golde DW and Marks PA eds) Alan R Liss, New
York, NY. 1983; 2:197-211.
15. Pagliardi GL, Pessano S, Palumbo A, Levis A, Bottero L, Ferrero D, Lange B, e Rovera G:
Dedifferentiation , maldifferentiation or arrested differentiation in human acute myelogenous leukemia.
13th International Cancer Congress on biology of Cancer (Miranda EA eds) Alan R Liss, New York, NY.
1983; Part C:65-73.
16. Pessano S, Palumbo A, Ferrero D, Pagliardi GL, Bottero L, Kai Lai S, Meo P, Carter C, Hubbel H,
Lange B, e Rovera G: Subpopulation heterogeneity in human acute myeloid leukemia determined by
monoclonal antibodies. Blood. 1984; 64:275-281. (I.F. 10.432)
17. Lange B, Ferrero D, Pessano S, Palumbo A, Faust J, Meo P, e Rovera G: Surface phenotype of
clonogenic cells in acute myeloid leukemia defined by monoclonal antibodies. Blood. 1984; 64:693-670.
(I.F. 10.432)
18. Lange B, Ferrero D, Pessano S, Hubbel H, Palumbo A, Kai Lai S, e Rovera G: Discrimination between
normal hemopoietic stem cells and myeloid leukemia cells using monoclonal antibodies. Minimal Residual
desease in Acute Leukemia (Lowenberg B and Hagenbeek A eds) Martinus Nijhoff Publishers, Boston
MA. 1984; 55-66.
19. Palumbo A, Minowada J, Erikson J, Croce CM, e Rovera G: Lineage infidelity of a human
myelogenous leukemia cell line. Blood. 1984; 64:1059-1063. (I.F. 10.432)
20. Pegoraro L, Palumbo A, Erikson J, Falda M, Giovinazzo B, Emanuel BS, Rovera G, Nowell PC, e
Croce CM: A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell
leukemia. Proc Natl Acad Sci USA. 1984; 81:7166-7170. (I.F. 9.643)
21. Garbarino G, Pagliardi GL, Palumbo A, Turco L, e Pegoraro L: Insulin requirement of human
leukemic cell lines. Experentia. 1985; 41:1067-1068.
22. Huebner K, Palumbo A, Isobe M, Kozak CA, Monaco S, Rovera G, Croce CM, e Curtis PJ: The alfaspectrin gene is on chromosome 1 in mouse and man. Proc Natl Acad Sci USA. 1985; 82:3790-3793. (I.F.
9.643)
23. Croce CM, Isobe M, Palumbo A, Puck J, Ming J, Tweardy D, Erikson J, Davis M, e Rovera G: Gene
for alpha-chain of human t-cell receptor: location on chromosome 14 region involved in T-cell neoplasms.
Science. 1985; 227:1044-1047. (I.F. 30.028)
24. Curtis PJ, Palumbo A, Ming J, Fraser P, Cioe L, Meo P, Shane S, e Rovera G: Sequence comparison of
human and murine erythrocyte spectrin cDNA. Gene. 1985; 36:357-362. (I.F. 2.721)
25. Palumbo A, Isobe M, Shane S, Rovera G, Demuth D, Curtis PJ, Ballantine M, Croce CM, e Showe
LC: Chromosomal localization of a human Band 3-like gene to region 7q35->7q36. Am J Hum Genet.
1986; 39:307-316. (I.F. 12.629)
26. Demuth DR, Showe LC, Ballantine M, Palumbo A, Fraser PJ, Cioe L, Rovera G, e Curtis PJ: Cloning
and structural characterization of a human non-erythroid band 3-like protein. EMBO Journal. 1986; 5:12051214. (I.F. 10.086)
27. Palumbo A, Rossino P, e Comoglio PM: Bombesin stimulation of c-fos and c-myc gene expression in
cultures of Swiss 3T3 cells. Exp Cell Res. 1986; 167:276-280. (I.F. 3.777)
28. Tweardy DJ, Cannizzaro LA, Palumbo A, Shane S, Huebner K, vanTuinen P, Ledbetter DH, Finan JB,
Nowell PC, e Rovera G: Molecular cloning and characterization of a cDNA for human granulocyte colony-
3
stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to
chromosome band 17q21. Oncogene Research. 1987; 1:209-220. (I.F. 6.582)
29. Palumbo A, Battaglio S, Dianzani U, Massaia M, e Boccadoro M: Expression of growth regulated
genes in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Oncogenes and Growth
Factors in Oncohematology (Aglietta M, Saglio G, Gavosto F eds). 1988;136-138.
30. Dianzani U, Pileri A, Boccadoro M, Palumbo A, Pioppo P, Bianchi A, Camponi A, Fossati G,
Battaglio S, Massaia M. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of
monoclonal gammopathies:correlation with diagnosis and disease status. Blood. 1988; 72:1064-1081. (I.F.
10.432)
31. Massaia M, Pileri A, Boccadoro M, Bianchi A, Palumbo A, Dianzani U. The generation of alloreactive
cytotoxic T lymphocytes (CTL) require the expression of ecto-5' nucleotidase activity. J.
Immunol.1988;141:3768-3775.
(I.F. 6.293)
32. Palumbo A, Pileri A, Battaglio S, Omede' P, Redoglia V, Massaia M, Dianzani U, Boccadoro M.
Monoclonal immunoglobulin rearrangement in peripheral lymphocytes of a patient with multiple myeloma.
Tumori. 1989; 7:1-3. (I.F. 0.701)
33. Palumbo A, Boccadoro M, Battaglio S, Corradini P, Giovinazzo B, Avanzi G, Ponzio G. Philadelphiapositive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. Cancer
Genet. Cytogenet. 1989; 39: 77-80. (I.F. 1.544)
34. Boccadoro M, Bianchi A, Dianzani U, Frieri R, Gallone G, Massaia M, Omede' P, Palumbo A, Pileri
A. Fattori prognostici nel mieloma multiplo. Haematologica. 1989; 74 (suppl. 5):347-357. (I.F. 5.032)
35. Palumbo A, Pileri A, Dianzani U, Massaia M, Boccadoro M, Calabretta B. Altered expression of
growth-regulated protoncogenes in human malignant plasma cells. Cancer Res. 1989; 49:4701-4705.
(I.F.7.656)
36. Boccadoro M, Frieri R, Battaglio S, Bianchi A, Dianzani U, Gallone G, Massaia M, Omede' P,
Palumbo A, Redoglia V, Tarella C, Pileri A. Mieloma Multiplo. Arch. Casa Sollievo della Sofferenza.
1989; 23:259-268.
37. Pileri A, Dianzani U, Frieri R, Gallone G, Massaia M, Palumbo A, Tarella C, Boccadoro M. Approccio
chemioterapico al mieloma multiplo. Atti XVI Corso Naz. Agg. in Ematologia Clinica. F. Mandelli, S.
Tura, M. Gobbi, G. Visani, PL. Zinzani, N. Vianelli Eds. Bologna giugno 1990;467-477.
38. Corradini P, Palumbo A, Battaglio S, Ponzio G, Boccadoro M, Pileri A. Analysis of the breakpoint
cluster region in essential thrombocythemia. Haematologica. 1990; 75:573-575. (I.F. 5.032)
39. Palumbo A, Garino A, Frieri R, Gallone G, Boccadoro M, Pileri A. Consolidation treatment with
dexamethasone and alpha-2b recombinant interferon further reduces the M-component level in multiple
myeloma patients responding to conventional induction chemotherapy. Haematologica. 1990;75:576-578.
(I.F. 5.032)
40. Palumbo A, Boccadoro M, Battaglio S, Corradini P, Tsichlis PN, Huebner K, Pileri A, Croce CM.
Human homologue of the Moloney Leukemia Virus Integration-4 Locus (MLVI-4), located 20 kb 3' of the
myc gene, is rearranged in multiple myelomas. Cancer Res. 1990; 50:6478-6482. (I.F. 7.656)
41. Palumbo A, Corradini P, Battaglio S, Omede' P, Coda R, Boccadoro M, Pileri A. Dual rearrangement
of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia. Eur. J. Haematol. 1991;
46:71-76. (I.F. 1.863)
4
42. Palumbo A, Lasota J, Battaglio S, Laforgia S, Huebner K, Boccadoro M, Croce CM, Pileri A.
Molecular analysis of the c-myc locus, its flanking chromosomal region, and the BCL-2 oncogene in
multiple myeloma. Abs. "III Int. Workshop on Multiple Myeloma from Biology to Therapy" - Eds. A.
Pileri, M. Boccadoro - Torino 1991; 29-30.
43. Pileri A, Boccadoro M, Battaglio S, Dianzani U, Massaia M, Omede' P, Palumbo A, Klein B, Bataille
R. New prognostic factors in multiple myeloma. Abs. "III Int. Workshop on Multiple Myeloma from
Biology to Therapy" - Eds. A. Pileri, M. Boccadoro - Torino 1991;81-82.
44. Boccadoro M, Pileri A, Avvisati G, Baccarani M, Caronia F, Cavo M, Frieri R, Gallone G, Lauta VM,
Liberati M, Marceno' R, Marmont F, Martelli M, Palumbo A, Papa G, Tribalto M, Dammacco F, Resegotti
L, Tura S, Mandelli F. Intensification of induction and maintenance therapy in multiple myeloma. Abs. "III
Int. Workshop on Multiple Myeloma from Biology to Therapy" - Eds. A. Pileri, M. Boccadoro - Torino
1991; 98-99.
45. Tarella C, Boccadoro M, Frieri R, Palumbo A, Pileri A, Siena S, Bregni M, Gandola L, Bonadonna G,
Gianni AM. High-dose sequential (HDS) pilot chemoradiotherapy for poor prognosis multiple myeloma. 2.
therapeutic efficacy and perspectives. Abs. "III Int. Workshop on Multiple Myeloma from Biology to
Therapy" - Eds. A. Pileri, M. Boccadoro - Torino 1991M;144-145.
46. Boccadoro M, Palumbo A, Pileri A. Biologia delle gammopatie monoclonali.
Regionale "Attualita' in Ematologia" - Torino 1991;3-7.
Atti Convegno
47. Grillo A, Palumbo A. Importanza del referto ematologico fornito da un analizzatore automatico per la
diagnosi ed il monitoraggio dei pazienti ematologici. Atti Convegno Regionale "Attualita' in Ematologia" Torino 1991;105-108.
48. Boccadoro M, Battaglio S, Dianzani U, Frieri R, Gallone G, Massaia M, Omedè P, Palumbo A, Pileri
A. Il Mieloma multiplo. Haematologica. 1991; 76 (suppl.3):100-106. (I.F. 5.032)
49. Boccadoro M, Battaglio S, Omede' P, Palumbo A, Fusaro A, Frieri R, Gallone G, Polloni R, Mosso R,
De Filippi PG, Pileri A. Increased serum neopterin concentration as indicator of disease severity and poor
survival in multiple myeloma. Eur. J. Haemat. 1991;1:305-309. (I.F. 1.863)
50. Palumbo A, Boccadoro M, Garino LA, Gallone G, Frieri R, Pileri A. Multiple myeloma: intensified
maintenance therapy with recombinant interferon--2b plus glucocorticoids. Eur. J. Haematol.1992;49:9397. (I.F. 1.863)
51. Tarella C, Omedè P, Boccadoro M, Palumbo A, Battaglio S, Pileri A. Early disappearance of murine
plasmocytoma stem cells in long-term bone marrow culture. Leukemia Res.1992; 16:743-750. (I.F. 2.483)
52. Palumbo A, Battaglio S, Astolfi M, Frieri R, Boccadoro M, Pileri A. Multiple independent class-switch
recombinations occurring within the same clone in myeloma. Br. J. Haematol. 1992; 82:678-680. (I.F.
4.498)
53. Pileri A, Palumbo A, Boccadoro M. Discrasie plasmacellulari. - Manuale di Terapia Medica Ed. L.
Resegotti - Casa Editrice Ambrosiana. 1993;496-501.
54. Palumbo A, Boccadoro M, Garino LA, Gallone G, Pileri A. Interferon plus glucocorticoids as
intensified maintenance therapy prolongs tumor control in refractory myeloma. Acta Haematol.
1993;90:71-76. (I.F. 1.564)
55. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowels DM, Boccadoro M, Pileri A.
Mutational activation of N-and K-RAS oncogenes in plasma cell dyscrasia. Blood. 1993; 81:2708-2713.
(I.F. 10.432)
5
56. Pileri A, Palumbo A, Boccadoro M. Multiple Myeloma: a tailored therapy for elderly patients. Hemat
Oncology. 1993; 11(suppl. 1):67-72. (I.F. 1.875)
57. Pileri A, Palumbo A, Frieri R, Massaia M, Boccadoro M. Prognostic factors in Multiple Myeloma. In
"Multiple Myeloma and related disorders". Eds F. Dammacco, B. Barlogie. Serona Symposia 1993;131137.
58. Palumbo A, Battaglio S, Napoli P, Omedè P, Fusaro A, Bruno B, Boccadoro M, Pileri A.
Recombinant interferon-gamma inhibits the growth of human myeloma cells in vitro. British Journal of
Haematology. 1994; 86:726-732. (I.F. 4.498)
59. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br. J.
Haematology. 1994; 88:754-759. (I.F. 4.498)
60. Palumbo A, Boccadoro M, Triolo S, Bruno B and Pileri A. Cyclophosphamide (3.6 g/m 2) therapy with
G-CSF support for resistant myeloma. Haematologica. 1994; 79:513-518. (I.F. 5.032)
61. Palumbo A, Bruno B, Boccadoro M, Pileri A. The effects of interferon- on human multiple myeloma
cells. Leukemia and Lymphoma. 1995;18:215-219. (I.F. 1.939)
62. Palumbo A, Battaglio S, Napoli P, Bruno B, Omedè P, Boccadoro M, Pileri A. Retinoic acid inhibits
the growth of human myeloma cells in vitro. Br. J. Haematol.1995; 89:555-560. (I.F. 4.498)
63. Palumbo A, Bruno B, Triolo S, Boccadoro M and Pileri A. Recombinant interferon- in a patient with
multiple myeloma. European Journal of Cancer. 1994; 11:1731-1734. (I.F. 4.167)
64. Pileri A, Massaia M, Tarella C, Corradini P, Ladetto M, Palumbo A, Boccadoro M. Mieloma multiplo:
Attualità e prospettive. Relazione al 35 Congr. Soc. It. di Ematologia, Cernobbio - settembre 1995;39-47.
65. Boccadoro M, Bruno B, Palumbo A, Pileri A. Interferons in multiple myeloma. Atti Eurocancer 95 Eds. M. Boiron, M. Marty - J. Libbey Eurotext - Paris 1995; 285-286.
66. Pileri A, Palumbo A, Boccadoro M. Current therapeutic options for
Haematologica. 1996; 81: 291-294. (I.F. 5.032)
multiple myeloma.
67. Pileri A, Caracciolo D, Corradini P, Ladetto M, Massaia M, Omedè P, Palumbo A, Tarella C,
Boccadoro M. Il trapianto autologo con progenitori emopoietici circolanti nel mieloma multiplo. Attualità
in Ematologia - Ed. M. Carotenuto - Casa Sollievo della Sofferenza, 1996;231-246.
68. Pileri A, Palumbo A, Triolo S, Boccadoro M. Autotrapianto di progenitori emopoietici circolanti nel
mieloma multiplo. Progressi in Ematologia Clinica. 1996; 15:91-106.
69. Pileri A, Palumbo A, Triolo S, Boccadoro M. Chemioterapia intensificata con supporto di progenitori
emopoietici circolanti. Seminari in Ematologia - a cura di E. Morra. 1996; 2:55-62.
70. Boccadoro M, Palumbo A, Argentino C, Dominietto A, Frieri R, Avvisati G, Comotti B, LautaVM,
Liberati M, Marmont F, Musto P, Tribalto M, Pileri A. Conventional induction treatments do not influence
overall survival in multiple myeloma. Br. J. Haematol. 1997; 96:333-337. (I.F. 4.498)
71. Palumbo A, Pileri A, Triolo S, Omedè P, Bruno B, Ciravegna G, Galliano M, Frieri R, Boccadoro M.
Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma
patients. Bone Marrow Transpl. 1997; 19:23-29. (I.F. 2.621)
72. Omedè P, Tarella C, Palumbo A, Argentino C, Caracciolo D, Corradini P, Dominietto A, Giaretta F,
Ravaglia R, Triolo R, Triolo S, Pileri A, Boccadoro M. Multiple myeloma: reduced plasma cell
contamination in peripheral blood progenitor cell (PBPC) collections performed after repeated high-dose
6
chemotherapy courses. Br. J. Haematol. 1997; 99: 685-691. (I.F. 4.498)
73. Triolo R, Omede P, Giaretta F, Ravaglia R, Battaglio S, Palumbo A, Dominietto A, Argentino C,
Triolo S, Pileri A, Boccadoro M. Cytofluorimetric evaluation of plasma cell proliferative activity in
monoclonal gammopathies. Eur J Histochem. 1997;41(Suppl 2):57-58. (I.F. 1.191)
74. Pileri A, Palumbo A, Boccadoro M. Chemioterapia intensificata con supporto di progenitori
emopoietici circolanti. La Cellula neoplastica: Biologia, diagnosi e terapia molecolare - a cura di P.
Comoglio e A. Nicolin - Ed. Periodici 1997; 384-396.
75. Pileri A, Palumbo A, Corradini P, Massaia M, Triolo S, Dominietto A, Argentino C, Ladetto M,
Tarella C, Boccadoro M. Nuovi aspetti terapeutici del mieloma multiplo. Atti “36° Congr. Naz. Soc. It. di
Ematologia” Catania 2-5/10/97; 55-64.
76. Majolino I, Corradini P, Scimè R, Santoro A, Tarella C, Cavallaro AM, Palumbo A, Indovina A,
Caracciolo D, Boccadoro M, Marcenò R, Pileri A. Allogeneic transplantation of unmanipulated peripheral
blood stem cells in patients with multiple myeloma. Bone Marrow Transpl. 1998; 22:449-455. (I.F. 2.621).
77. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, Van Lint MT, Bacigalupo A,
Santoro A, Musso M, Majolino I, Boccadoro M, Pileri A. Molecular and clinical remissions in multiple
myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol.
1999;17:208-215. (I.F. 13.598)
78. Boccadoro M, Tarella C, Palumbo A, Argentino C, Triolo S, Dominietto A, Callea V, Lauta VM,
Molica S, Musto P, Marmont F, Gianni AM, Pileri A. Multiple myeloma: analysis of patient subgroups
who benefit from high-dose vs conventional chemotherapy according to 2- microglobulin and plasma cell
labelling index. Haematologica. 1999; 84: 905-910. (I.F. 5.032)
79. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omedè P, Tarella C, Pileri A,
Boccadoro M. Dose- intensive melphalan with stem cell support (MEL100) is superior to standard
treatment in elderly myeloma patients. Blood . 1999; 94:1248-1253. (I.F. 10.432)
80. Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, Grasso M, Liberati M,
Lotesoriere C, Marceno R, Marmont F, Musto P, Petrucci MT, Spriano M, Pileri A, Boccadoro M. Doseintensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly
myeloma patients. Haematologica. 2000; 85:508-513. (I.F. 5.032)
81. Triolo S, Palumbo A, Pileri A, Boccadoro M. Mieloma Multiplo: nuove strategie terapeutiche.
Medicina Subalpina 2. 2000;13-17.
82. Boccadoro M, Omedè P, Dominietto A, Palumbo A, Bringhen S, Giaretta F, Ortolano B, Triolo S,
Pileri A. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients
treated with intensified chemotherapy and PBPC support. Bone Marrow Transpl. 2000; 25:25-29. (I.F.
2.621)
83. Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, Grasso M, Liberati M,
Lotesoriere C, Marcenò R, Marmont F, Musto P, Petrucci MT, Spriano M, Pileri A, Boccadoro M. Doseintensive melphalan with stem cell support /CM regimen is effective and well tolerated in elderly myeloma
patients. Haematologica. 2000; 85:508-513. (IF 5.032)
84. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A,
Boccadoro M. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced
myeloma. Haematologica. 2001; 86:399-403. (I.F.5.032)
85. Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, Rus C, Bertola A,
Giaccone L, Omedè P, Musto P, Pileri A. Oral melphalan at diagnosis hampers adeguate collection of
7
peripheral blood progenitor cells in multiple myeloma. Haematologica. 2002; 87:846-850. (I.F. 5.032)
86. Boccadoro M, Palumbo A. New developments and treatment in multiple myeloma: new drugs in the
treatment of multiple myeloma. Annals of Oncology. 2002; 4:55-58. (I.F.5.179)
87. Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Drandi D, Volpato F, Giaccone L, Giaretta F,
Palumbo A, Bruno B, Pileri A, Gribben JG, Boccadoro M. Related Articles, Links Real-time polymerase
chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. Exp
Hematol. 2002;30(6):529-36. (IF 3.408)
88. Ladetto M, Drandi D, Volpato F, Astolfi M, Voena C, Compagno M, Novarino A, Pollio B, Addeo A,
Ricca I, Falco P, Cavallo F, Vallet S, Corradini P, Pileri A, Tamponi G, Palumbo A, Bertetto O,
Boccadoro M, Tarella C. PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal
subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. J. Clin. Oncology.
2003; 21:1398-1403. (I.F. 13.598)
89. Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M, Bruno B, Rus C. Barbui A,
Caravita T, Musto P, Pescosta N, Rossini F, Vignetti M, Boccadoro M. Multiple myeloma: comparison of
two dose-intensive melphalan regimens (100 vs 200 mg/m2 ). Leukemia. 2004; 18:133-138. (I.F. 6.146)
90. Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, Ciaramitaro P, Palumbo A,
Bergamasco B, Cocito D. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological
features. Acta Neurol. Scand. 2004; 109:188-193. (I.F. 1.833)
91. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M. New drugs for
treatment of multiple myeloma. Lancet Oncol. 2004; 5:430-442. (I.F. 10.119)
92. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, Bringhen S, Musto P, Pregno P,
Caravita T, Ciccone G, Boccadoro M. Efficacy of low-dose thalidomide and dexamethasone as first salvage
regimen in multiple myeloma. Hematol J. 2004;5(4):318-324. (I.F. 5.032)
93. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui
A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P,
Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G,
Boccadoro M. Intermediate-Dose Melphalan Improves Survival of Myeloma Patients Aged 50-70: Results
of A Randomised Controlled Trial. Blood. 2004; 104(10):3052-3057. (I.F. 10.432)
94. Palumbo A, Boccadoro M. Mieloma Multiplo: Fattori prognostici e strategie terapeutiche. Ematologia
Pratica. 2004; 5: 5-1.
95. Rus C, Bazzan M, Palumbo A, Bringhen S, Boccadoro M. Thalidomide in front line treatment in
multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J
Thromb Haemost. 2004;2(11):2063-2065. (I.F. 5.138)
96. Falco P, Bertola A, Bringhen S, Cavallo F, Boccadoro M, Palumbo A. Successful management of
immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. Hematol J.
2004;5(5):456-457. (I.F. 5.032)
97. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M,
Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M. Effector gammadelta T cells and
tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005; 19(4):664-670.
(I.F. 6.146)
98. Ladetto M, Vallet S, Trojan A, Dell'aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A,
Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci
A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omede P, Palumbo A, Boccadoro
8
M. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent
predictor of poor outcome. Blood. 2005; 105(12):4784-4791. (I.F. 10.432)
99. Anderson KC, Palumbo A; Multiple Myeloma Research Foundation. Treatment options for older
myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park).
2005;19(4):447-450.
100. Boccadoro M, Blade J, Attal M, Palumbo A. The future role of thalidomide in multiple myeloma.
Acta Haematol. 2005;114(1):18-22. (I.F. 1.564)
101. Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Barbui AM, Nunzi M, Boccadoro M;
Italian Multiple Myeloma Study Group. Correlation between fatigue and hemoglobin level in multiple
myeloma patients: results of a cross-sectional study. Haematologica. 2005;90(6):858-860 (IF 5.032)
102. Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M,
Cavallo F, Sala AL, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'olio M, Bodenizza C, Greco MM,
Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A. Bortezomib (Velcade) for
progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res. 2005;
30(3):283-285. (IF 2.483)
103. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C,
Boccadoro M. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Cancer. 2005;104(7):1428-1433. (IF 4.582)
104. Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo
F, Ciccone G, Boccadoro M. Thalidomide plus dexamethasone is an effective salvage regimen for
myeloma patients relapsing after autologous transplant. Eur J Haematol. 2005;75(5):391-395. (IF 1.863)
105. Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J
Haematol. 2006;76(4):273-277. (I.F. 1.863)
106. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M,
Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT,
Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network,
GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and
prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet.
2006;367(9513):825-831. (I.F. 25.800)
107. Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C,
Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M. Intermediate-dose melphalan (100
mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or
relapsed myeloma. Clin Lymphoma Myeloma. 2006; 6(6):475-477. (I.F. 2.444)
108. Caravita T, De Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: Efficacy comparisons
in solid tumors and hematologic malignancies. Nat Clin Pract Oncol. 2006;3(7):374-387. (I.F. 5.364)
109. Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network,
Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed
myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb
Haemost. 2006;4(8):1842-1845 (I.F. 5.138)
110. Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A. Investigational treatments for
multiple myeloma. Expert Opin Investig Drugs. 2006;15(12):1565-1582. (I.F. 3.174)
9
111. Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C,
Boccadoro M, Leoni P, Palumbo A. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin
vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol.
2007;78(4):297-302. (I.F. 1.863)
112. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T,
Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M. Bortezomib, melphalan,
prednisone and thalidomide for relapsed multiple myeloma.Blood. Blood. 2007;109(7):2767-2772. (I.F.
10.432)
113. Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, Palumbo A. Melphalan and its role
in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7(7):945-957.
114. Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B,
Boccadoro M. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma
patients who receive thalidomide as salvage therapy. Cancer. 2007;110(4):824-829. (I.F. 4.582)
115. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R,
Palumbo A; GISMM Cooperative Group; GISL Cooperative Group; GIMEMA Cooperative Group.
Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109(11):2285-2290.
(I.F. 4.582)
116. Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A. The treatment of the elderly multiple
myeloma patients. Leuk Lymphoma. 2007;48(3):469-480. (I.F. 1.939)
117. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R,
Omede P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb
R, Ciccone G, Boccadoro M. A comparison of allografting with autografting for newly diagnosed
myeloma. N Engl J Med. 2007;356(11):1110-1120. (I.F. 51.296)
118. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G,
Omede P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foa R, Knight R, Zeldis JB, Boccadoro M,
Petrucci MT. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A
Report From the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007;25(28):4459-4465. (I.F.
17.157)
119. Palumbo A, Boccadoro M. A new standard of care for elderly patients with myeloma. Lancet.
2007;370(9594):1191-1192. (I.F. 25.800)
120. Rajkumar SV, Palumbo A. Management of newly diagnosed myeloma. Hematol Oncol Clin North
Am. 2007;21(6):1141-1156. (I.F. 2.041)
121. Palumbo A, Avonto I, Falco P, Cavallo F, Caravita T, Petrucci M.T., Cavo M, Boccadoro M. Novel
treatment approaches in multiple myeloma. EHA – Hematology Education. 2007; 1(1):108-114.
122. Palumbo A, Avonto I, Bringhen S, Falcone A, Liberati M, Boccadoro M. Hematologic cancer in the
elderly: new and existing therapeutic strategies. American Society of Clinical Oncology – Educational
Book. 2007; 288-294.
123. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia
M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I,
Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C,
Ovaa H, Bernareggi A, Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumorselective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765-2775. (I.F. 10.432)
10
1
0
124. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau
J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D,
Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S,
Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA;
International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated
thrombosis in myeloma. Leukemia. 2008;22(2):414-423. (I.F. 8.634)
125. Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto
V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M. Bortezomib, doxorubicin and
dexamethasone in advanced multiple myeloma. Ann Oncol. 2008; 19(6):1160-5 (I.F. 4.935)
126. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomidebased therapy for multiple myeloma. Cancer. 2008 Apr 1;112(7):1522-8. PMID: 18278812 (I.F. 5.238)
127. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu
K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C,
Cavo M, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients under age 50 presents with more
favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma
Working Group. Blood. 2008; 111: 4039 (I.F. 10.432)
128. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A,
Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma: 10 years later.
Blood. 2008; 111:3968 (I.F. 10.432)
129. Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H. Lenalidomide: A new
therapy for multiple myeloma. Cancer Treat Rev. 2008 May;34(3):283-91. Review. PMID: 18230411 (I.F.
4.729)
130. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. Lenalidomide and
its role in the management of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. (I.F.
2.296)
131. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R,
Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P,
Cavo M, Boccadoro M. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple
myeloma: updated results of a randomized, controlled trial. Blood. 2008; 112(8):3107-14 (I.F. 10.432)
132. Cavallo F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed
multiple myeloma. Ther Clin Risk Manag. 2007 Aug;3(4):543-552. PMID: 18472975
133. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide:
Mechanism-based potential drug combinations. Leuk Lymphoma. 2008 Jul;49(7):1238-45. PMID:
18452080 (I.F. 1.939)
134. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci
MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV,
Anderson KC, Esseltine DL, Liu K, Cakana A, Van de Velde H, Richardson PG, for the VISTA-MMY3002 study investigators. Bortezomib plus Melphalan-Prednisone vs Melphalan-Prednisone in untreated
multiple myeloma patients ineligible for stem cell transplantation. The New England Journal of Medicine
2008 Aug 28;359(9):906-17 PMID: 18753647 (I.F. 50.017)
135. Palumbo A, Dimopoulos M, Miguel JS, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von
Lilienfeld-Toal M, Sonneveld P. Lenalidomide in combination with dexamethasone for the treatment of
relapsed or refractory multiple myeloma. Blood Rev. 2008 Sep 5. PMID: 18774632 [PubMed - as supplied
by publisher] (I.F. 7.816)
11
1
1
136. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H,
Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM.
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U
S A. 2008 Sep 2;105(35):12885-90. PMID: 18728182 (I.F. 9.380)
137. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena
G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; for the GIMEMA (Italian Group for Adult
Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. A
multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with
asymptomatic myeloma. Cancer. 2008; 113(7):1588-95 PMID: 18683218 (I.F. 5.238)
138. Palumbo A, Magarotto V, Gay F, Falco P, Bringhen S, Boccadoro M. Update on recent developments
for patients with newly diagnosed multiple myeloma. Ann N Y Acad Sci. 2008 Sep;1138:19-21(I.F. 2.303).
139. Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S,
Boccadoro M, Palumbo A; Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working
Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. Role of thalidomide in previously
untreated patients with multiple myeloma. Expert Rev Anticancer Ther. 2008 Oct;8(10):1569-80.
PMID: 18925849 (I.F. 2.296)
140. Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA,
LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J,
Durie BG; International Myeloma Working Group. The role of vertebral augmentation in multiple
myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 2008 Aug;22(8):147984. Epub 2008 May 29. (I.F. 8.634)
141. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. Lenalidomide and
its role in the management of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74.
Review. PMID: 18533796 (I.F. 2.296)
142. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R,
Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P,
Cavo M, Boccadoro M. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple
myeloma: updated results of a randomized controlled trial. Blood. 2008 Oct 15;112(8):3107-14. Epub 2008
May 27. PMID: 18505783 (IF 10.432)
143. Palumbo A, Dimopoulos M, Miguel JS, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von
Lilienfeld-Toal M, Sonneveld P. Lenalidomide in combination with dexamethasone for the treatment of
relapsed or refractory multiple myeloma. Blood Rev. 2009; 23(2):87-93 (I.F. 7.816)
144. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F,
Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca
A, Cavo M, Boccadoro M, Palumbo A. Considerations in the treatment of multiple myeloma: a consensus
statement from Italian experts. Eur J Haematol. 2009 Feb;82(2):93-105. Epub 2008 Nov 6. PMID:
19018865 (IF 2.237)
145. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009 Mar;23(3):44956. Epub 2008 Nov 13. Review. PMID: 19005483 (IF 8.634)
146. Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M,
Anderson KC, Iacobelli M, Richardson PG. Preclinical studies in support of defibrotide for the treatment of
multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15;15(4):1210-21. PMID: 19228727
(IF 6.488)
12
1
2
147. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A,
Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo
A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Nonmyeloablative
allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di
Midollo. Blood. 2009 Apr 2;113(14):3375-82. Epub 2008 Dec 8. PMID: 19064724 (IF 10.432)
148. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S,
Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the
incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk
Lymphoma. 2008 Nov;49(11):2156-62. PMID: 19021059 (IF 1.939)
149. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J,
Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal
M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D,
Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working
Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple
myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. Epub 2008 Nov 20. Review. PMID:
19020545 (IF 8.634)
150. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo
R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies
F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M,
Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial
S. International Myeloma Working Group guidelines for the management of multiple myeloma patients
ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009
Jun 4. [Epub ahead of print] PMID: 19494840 (IF 8.634)
151. Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, Larocca A, Magarotto V, Gozzetti A,
Luraschi A, Morabito F, Nozza A, Knight RD, Zeldis JB, Boccadoro M, Petrucci MT. Melphalan,
prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia
and time-to-event results. Clin Lymphoma Myeloma. 2009 Apr;9(2):145-50. PMID: 19406725 (IF 1.596)
152. Kastritis E, Palumbo A, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma. Semin
Hematol. 2009 Apr;46(2):143-57. Review. PMID: 19389498 (IF 3.070)
153. Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro
AM, Varettoni M, Gay F, Morra E, Lazzarino M. Long-term outcome in relapsed and refractory multiple
myeloma treated with thalidomide. Balancing efficacy and side-effects. Leuk Res. 2009 Sep;33(9):e145-9.
Epub 2009 Apr 16. PMID: 19375164 (IF 2.390)
154. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL,
Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson
KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar
SV. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following
initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens. Blood. 2009;
114(9):1729-35. (IF 10.432)
155. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi
NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S,
Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro
M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R,
Richardson PG, Niesvizky R, Rajkumar SV, Durie BG. International myeloma working group (IMWG)
consensus statement and guidelines regarding the current status of stem cell collection and high-dose
therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Jun 25. [Epub ahead
of print] PMID: 19554029 (IF 8.634)
13
1
3
156. Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F, Cipriani A, Palumbo A,
Boccadoro M. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not
prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem. 2009
Aug;55(8):1510-6. Epub 2009 Jun 11. PMID: 19520760 (IF 5.579)
157. Gay F, Palumbo A. Multiple myeloma: management of adverse events. Med Oncol. 2009 Jul 7. [Epub
ahead of print] PMID: 19582597 (IF 1.134)
158. Musto P, D'Auria F, Pietrantuono G, Baldini L, Bringhen S, Caravita T, Di Raimondo F, Morabito F,
Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A. First-line Treatment of
Multiple Myeloma in Elderly Patients: The Gimema (Gruppo Italiano Malattie EMatologiche dell'Adulto)
Multiple Myeloma Working Party Perspective. Curr Drug Targets. 2009; [Epub ahead of print] (IF 4.187)
159. Morabito F, Gentile M, Gay F, Bringhen S, Mazzone C, Vigna E, Musto P, Di Raimondo F, Palumbo
A. Insights into defibrotide: an updated review. Expert Opin Biol Ther. 2009;9(6):763-72. (IF 3.475)
160. Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, Larocca A, Magarotto V, Gozzetti A,
Luraschi A, Morabito F, Nozza A, Knight RD, Zeldis JB, Boccadoro M, Petrucci MT. Melphalan,
prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia
and time-to-event results. Clin Lymphoma Myeloma. 2009;9(2):145-50. (IF 1.596)
161. Magarotto V, Palumbo A. Evolving role of novel agents for maintenance therapy in myeloma. Cancer
J. 2009 Nov-Dec;15(6):494-501. (IF 2.769)
162. Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or
sequencing. Hematology Am Soc Hematol Educ Program. 2009:566-77.
163. Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi
C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano
V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M. Melphalan 200 mg/m2 versus
Melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study.
Blood. 2009 Dec 1. [Epub ahead of print] (IF 10.432)
164. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E,
Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di
Raimondo F, Boccadoro M, Palumbo A, Cavo M. Safety and efficacy of bortezomib-based regimens for
multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network
GIMEMA. Eur J Haematol. 2009 Nov 23. [Epub ahead of print] (IF 2.237)
165. Palumbo A, Gay F. Towards a new standard of care for patients with myeloma? Lancet Oncol. 2009
Oct 21. [Epub ahead of print] (IF 13.283)
166. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo
R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies
F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M,
Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial
S; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma
patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
Leukemia. 2009 Oct;23(10):1716-30. Epub 2009 Jun 4. (IF 8.634)
167. Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo
F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M,
Richardson P; for the Italian Multiple Myeloma Network, GIMEMA. Melphalan, prednisone, thalidomide
14
1
4
and defibrotide in relapsed/refractory multiple myeloma: results of multicenter phase I/II trial.
Haematologica. 2010 Jan 6. [Epub ahead of print] (IF 5.978)
168. Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo
G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM,
Rossi G, Corradini P, Boccadoro M. Bortezomib As Induction Before Autologous Transplantation,
Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. J Clin
Oncol. 2010 Jan 4. [Epub ahead of print] (IF 17.157)
169. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J. The current status and
future of multiple myeloma in the clinic. Clin Lymphoma Myeloma. 2010 Feb;10(1):E1-16. (IF 1.596)
15
1
5